Related Experiment Videos
[Treatment of hyperlipidemia in patients with ischemic heart disease]
P Pauciullo1, C Lirato, C Sapio
1Clinica Medica, Istituto di Medicina Interna e Malattie Dismetaboliche, II Facoltà di Medicina e Chirurgia, Università degli Studi Federico II, Napoli.
Insights
Lipid-lowering treatment significantly benefits patients with coronary heart disease. Studies show cholesterol reduction decreases heart attacks and promotes plaque regression, improving vascular tone.
Area of Science:
- Cardiology
- Vascular Biology
- Clinical Research
Context:
- Investigating the benefits of lipid-lowering treatment in coronary heart disease (CHD).
- Evaluating treatment efficacy over the last two decades.
- Focusing on clinical events, atherosclerotic plaque dynamics, and vascular tone.
Purpose:
- To determine if patients with coronary heart disease benefit from lipid-lowering treatment.
- To synthesize evidence from major secondary prevention trials.
Summary:
- Eight secondary prevention trials demonstrated a 15% reduction in myocardial infarctions for every 10% decrease in serum cholesterol.
- Seven trials using coronary angiography indicated that a 20% cholesterol reduction can lead to plaque regression or slowed progression within 2 years.
- In vivo studies revealed hypercholesterolemic individuals exhibit coronary spasms, while those with low cholesterol show vasodilation.
Impact:
- Lipid-lowering therapy is crucial for secondary prevention in CHD.
- Treatment effectively reduces cardiovascular events and improves atherosclerotic plaque burden.
- Understanding vascular tone changes highlights a key mechanism of benefit.
Abstract:
Do patients with coronary heart disease benefit from lipid lowering treatment? In the last 20 years clinical research has addressed this question considering 3 different endpoints: clinical events, progression and regression of atherosclerotic plaque, and vascular tone. Eight major secondary prevention trials showed that a 10% reduction in serum cholesterol led to reduction of 15% in the number of all myocardial infarctions. Seven secondary prevention trials based on coronary angiography showed that a 20% serum cholesterol reduction can induce regression and/or reduce progression of plaques in as short as 2 years. In vivo experiments have also shown that coronary spasms are the most common response to various stimulations in hypercholesterolemic individuals; vasodilation is the most common coronary response in subjects with low cholesterol levels.